Latest From Therapeutic Advances in Hematology

Journal Highlights

• Launched in 2010
• Gold open access journal – all articles are made freely available online immediately upon publication
• Rigorous peer review
• Listed in PubMed and indexed in Web of Science and Science Citation Index Expanded (SCIE)
• A leading gold open access journal in hematology
• Over 300,000 full-text article views annually

Therapeutic Advances in Hematology (TAH) is a peer-reviewed open access journal which focuses on delivering the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. Please see the Aims and Scope tab for further information.

The journal is a member of the Committee on Publication Ethics (COPE).

This journal flipped to open access on July 1, 2018.

Diversity, Equity and Inclusion Statement

Therapeutic Advances in Hematology (TAH) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the hematology community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information

Submit your manuscript today at http://mc.manuscriptcentral.com/tah.